MAPT and supranuclear palsy, progressive, 1: Clinical studies and trials are focusing on therapies targeting tau for PSP and two main strategies have been proposed, which are focused on the elimination of pathological tau aggregates or reducing MAPT expression with ASO therapies to reduce the amount of tau protein transcribed to prevent its aggregation [5].